Liraglutide biosimilar (Etinpro/Sciwind)

利拉鲁肽生物类似药（亦庄国际蛋白/先为达）

Report date: 2022/10/25 16:00:16

Base Information

Drug NameLiraglutide biosimilar (Etinpro/Sciwind)
Drug Alias NameN/A
ClassificationBiologics > Protein drugs > Recombinant polypeptideBiologics > Biosimilar
Mechanisms of ActionGlucagon-like peptide 1 receptor agonists
TargetsGlucagon-like peptide 1 receptor
Therapy Area/IndicationsDiabetes Mellitus, Type 2
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesEtinpro (Beijing) Co LtdHangzhou Sciwind Biotechnology Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesHangzhou Sciwind Biotechnology Co LtdEtinpro (Beijing) Co Ltd
Inactive CompaniesN/A
Active IndicationsDiabetes Mellitus, Type 2
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A